Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-06-18
DOI
10.1007/s12325-023-02568-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials
- (2023) Andrew Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- A real‐life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis
- (2022) Alessandra Michelucci et al. Dermatologic Therapy
- Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
- (2022) Matteo Megna et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
- (2022) Matteo Megna et al. Dermatologic Therapy
- Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
- (2022) Matteo Megna et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Real‐world evidence from the non‐interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab
- (2022) S. Gerdes et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2
- (2022) AP Fernandez et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence
- (2022) David Medina-Catalán et al. International Journal of Clinical Pharmacy
- The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience
- (2022) Angelo Ruggiero et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Treating psoriasis in the elderly: biologics and small molecules
- (2022) Matteo Megna et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Pathogenesis-oriented therapy of psoriasis using biologics
- (2022) Wolf-Henning Boehncke et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- New frontiers in personalized medicine in psoriasis
- (2022) Elisa Camela et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
- (2022) Marco Galluzzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
- (2022) Luca Mastorino et al. ACTA DERMATO-VENEREOLOGICA
- Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT
- (2022) Athanasios Tsianakas et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study— IL PSO ( Italian landscape psoriasis )
- (2022) Alessandra Narcisi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
- (2022) Gabrielle Becher et al. Dermatology and Therapy
- Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies
- (2022) Diamant Thaçi et al. Dermatology and Therapy
- Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study
- (2022) Luigi Gargiulo et al. Dermatology and Therapy
- Guselkumab: Mid‐term effectiveness, drug survival and safety in real clinical practice
- (2021) Ricardo Ruiz‐Villaverde et al. Dermatologic Therapy
- Five‐year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2)
- (2021) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
- (2021) Shinichi Imafuku et al. JOURNAL OF DERMATOLOGY
- Psoriasis
- (2021) Christopher E M Griffiths et al. LANCET
- Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up
- (2021) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial
- (2021) Sascha Gerdes et al. JOURNAL OF DERMATOLOGY
- Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate‐to‐severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
- (2021) D. Thaçi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Psoriasis Prevalence in Adults in the United States
- (2021) April W. Armstrong et al. JAMA Dermatology
- Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
- (2021) Spyridon Gkalpakiotis et al. Dermatology and Therapy
- Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
- (2021) Riccardo G. Borroni et al. ACTA DERMATO-VENEREOLOGICA
- Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
- (2021) A. Ruggiero et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients
- (2021) Katharina A. Drerup et al. DERMATOLOGY
- Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations
- (2021) Marco Galluzzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
- (2021) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review
- (2020) Masahiro Kamata et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Guselkumab: Short‐term effectiveness and safety in real clinical practice
- (2020) Lourdes Rodriguez Fernandez‐Freire et al. Dermatologic Therapy
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
- (2020) April W. Armstrong et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator–controlled VOYAGE 1/2 trials
- (2020) Sang Woong Youn et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials
- (2020) L. Puig et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis
- (2020) Andrew Blauvelt et al. JAMA Dermatology
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open‐label, efficacy assessor‐blinded clinical trial
- (2020) R.B. Warren et al. BRITISH JOURNAL OF DERMATOLOGY
- Real‐life experience of guselkumab in patients with psoriasis
- (2020) Igor Snast et al. Dermatologic Therapy
- Long-term Single Center Experience in Treating Plaque Psoriasis With Guselkumab
- (2020) Khalad Maliyar et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
- (2020) Matteo Megna et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
- (2020) Marco Galluzzo et al. Journal of Clinical Medicine
- The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
- (2020) M. Alan Menter et al. Journal of Drugs in Dermatology
- Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study
- (2020) Angelo Ruggiero et al. Dermatologic Therapy
- Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis
- (2019) J.J. Crowley et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis
- (2019) M. Gooderham et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks
- (2019) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
- (2019) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
- (2019) Kristian Reich et al. LANCET
- Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis
- (2019) Tadashi Terui et al. JAMA Dermatology
- Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council
- (2019) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Incidence of cardiovascular events among tildrakizumab‐treated patients with moderate‐to‐severe plaque psoriasis: pooled data from three large randomised clinical trials
- (2019) R. Bissonnette et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
- (2019) Kristian Reich et al. LANCET
- Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2
- (2019) Kristian Reich et al. JOURNAL OF DERMATOLOGY
- Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
- (2019) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials
- (2018) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents
- (2018) Shivani B. Kaushik et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections
- (2018) Shivani B. Kaushik et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomised VOYAGE 1 and VOYAGE 2 studies
- (2018) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- The role of IL 23 in the treatment of psoriasis
- (2017) Lluís Puig Expert Review of Clinical Immunology
- Psoriasis and comorbid diseases
- (2017) Junko Takeshita et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Psoriasis
- (2015) Wolf-Henning Boehncke et al. LANCET
- Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?
- (2013) Clara De Simone et al. EXPERT OPINION ON BIOLOGICAL THERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started